Ally Bridge Group NY LLC acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 437,391 shares of the company's stock, valued at approximately $5,944,000. Amylyx Pharmaceuticals makes up approximately 3.6%
Alpha Wave Global LP increased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) by 18.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 327,312 shares of the company's stock after acquiring an additional 51,470 shares during the period. Amylyx Pharmaceuticals
Amylyx Pharmaceuticals (NASDAQ: AMLX) executives told investors the company entered 2026 with a focus on advancing avexitide toward what could become the first FDA-approved therapy for post-bariatric hypoglycemia (PBH), while continuing early-stage work across its pipeline and maintaining a cash runway management said extends into 2028. Avexitide's pivotal trial: timeline, endpoint, and powering assumptions Co-CEO Justin
Amylyx Pharmaceuticals (AMLX) is downgraded from 'Strong Buy' to 'Buy' following the discontinuation of AMX0035 for PSP. Company's investment thesis now centers on avexitide, a GLP-1 receptor antagonist in phase 3 LUCIDITY for post-bariatric hypoglycemia, with topline data expected Q3 2026. The company maintains a strong cash position [$317M, funding into 2028], supporting key milestones including potential avexitide commercialization.
Amylyx Pharmaceuticals (NASDAQ: AMLX) executives outlined a slate of milestones they expect to shape the company's near-term trajectory during TD Cowen's 46th Annual Healthcare Conference, with co-CEOs Josh Cohen and Justin Klee emphasizing that 2026 could be "transformative" primarily due to a pivotal readout for avexitide in post-bariatric hypoglycemia (PBH). Avexitide Phase 3 timeline and near-term
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “In 2026, our primary focus is on our Phase 3 LUCIDITY trial of av.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences.
Theravance Biopharma (NASDAQ: TBPH - Get Free Report) and Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares Theravance Biopharma and
Joshua B Cohen sold 138,167 shares for a total transaction value of ~$1.9 million on Jan. 15 and Jan. 16, 2026, at a weighted average price of $13.59 per share. This sale represented 3.93% of Cohen's direct holdings at the time, reducing his direct position from 3,517,632 to 3,379,465 shares.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S (“Gubra”), a company specializing in peptide-based drug discovery and preclinical contract research services. “We are very.
Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
New York City-based Commodore Capital bought nearly 4.1 million shares, increasing portfolio value by an estimated $55 million. The position represents 2.7% of 13F reportable assets under management (AUM).
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
California-based TCG Crossover bought 300,000 shares of Amylyx Pharmaceuticals for an estimated $46.8 million in the third quarter. At quarter-end, TCG Crossover reported holding 6.2 million total shares of Amylyx shares valued at $84.9 million.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). If you currently own shares of Amylyx Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=22470 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). If you currently own shares of Amylyx Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=22470 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg.